AstraZeneca Covid-19 Antibody Treatment Suffers Setback
AstraZeneca’s coronavirus antibody treatment failed in late-stage clinical trials to achieve its primary goal of preventing symptomatic Covid-19 in people recently exposed to the virus, the latest disappointment in a broader search for reliable post-infection therapies.